Evidence map›Paper›PMID 38628315›Full record

ArticleFrontiers in cardiovascular medicine2024

Differential impact of fentanyl and morphine doses on ticagrelor-induced platelet inhibition in ST-segment elevation myocardial infarction: a subgroup analysis from the PERSEUS randomized trial.

Dorian Garin, Sophie Degrauwe, Federico Carbone, Yazan Musayeb, Nathalie Lauriers, Marco Valgimigli, Juan F Iglesias

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02531165 (Comparison of Analgesia With Fentanyl and Morphine on Platelet Inhibition After Pre-hospital Ticagrelor Administration in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02531165 nacompletednot on this map

Comparison of Analgesia With Fentanyl and Morphine on Platelet Inhibition After Pre-hospital Ticagrelor Administration in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

TypeinterventionalSponsorCentre Hospitalier Universitaire VaudoisRan2015 to 2018Enrolled38ConditionsAcute Myocardial InfarctionArmsFentanyl, Morphine, Ticagrelor, Aspirin, Unfractioned Heparin
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Dorian GarinDepartment of Cardiology, Geneva University Hospitals, Geneva, Switzerland.
Sophie DegrauweDepartment of Cardiology, Geneva University Hospitals, Geneva, Switzerland.
Federico CarboneDepartment of Internal Medicine, First Clinic of Internal Medicine, University of Genoa, Genoa, Italy.
Yazan MusayebDepartment of Cardiology, Geneva University Hospitals, Geneva, Switzerland.
Nathalie LauriersDepartment of Cardiology, Lausanne University Hospital, Lausanne, Switzerland.
Marco ValgimigliIstituto Cardiocentro Ticino, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Juan F IglesiasDepartment of Cardiology, Geneva University Hospitals, Geneva, Switzerland.
University Hospital of Geneva · CHEnte Ospedaliero Cantonale · CHOspedale Policlinico San Martino · ITUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Among patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI), intravenous fentanyl does not enhance ticagrelor-induced platelet inhibition within 2 h compared to morphine. The impact of the total dose of fentanyl and morphine received on ticagrelor pharmacodynamic and pharmacokinetic responses in patients with STEMI remains however undetermined. Materials and methods: We performed a post-hoc subanalysis of the prospective, open-label, single-center, randomized PERSEUS trial (NCT02531165) that compared treatment with intravenous fentanyl vs. morphine among symptomatic patients with STEMI treated with primary PCI after ticagrelor pretreatment. Patients from the same population as PERSEUS were further stratified according to the total dose of intravenous opioids received. The primary outcome was platelet reactivity using P2Y Results: 38 patients with STEMI were included between December 18, 2015, and June 22, 2017. Baseline clinical and procedural characteristics were similar between low- and high-dose opioid subgroups. At 2 h, there was a significant correlation between PRU and both raw [regression coefficient (B), 0.51; 95% confidence interval (CI), 0.02-0.99; Conclusion: In symptomatic patients with STEMI who underwent primary PCI after ticagrelor pretreatment and who received intravenous opioids, we found a dose-dependent relationship between the administration of intravenous fentanyl, but not morphine, and ticagrelor-induced platelet inhibition.

Indexed as

dosefentanylpharmacodynamicspharmacokineticsST-segment elevation myocardial infarctionticagrelor

Identifiers

PMID38628315
PMCPMC11018886
OpenAlexW4393443521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.